Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
January 09, 2023 08:20 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge...
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:01 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will present at the upcoming 41st Annual J.P....
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
December 24, 2022 00:01 ET
|
Coherus BioSciences, Inc.
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences are actively engaged in ongoing discussions...
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
November 08, 2022 16:01 ET
|
Coherus BioSciences, Inc.
– UDENYCA® net sales of $45.4 million in the third quarter 2022 –– CIMERLI™ launched in the United States on October 3rd –– Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and...
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
November 01, 2022 07:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
October 12, 2022 07:30 ET
|
Coherus BioSciences, Inc.; Shanghai Junshi Biosciences Co., Ltd
– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations,...
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
September 19, 2022 07:30 ET
|
Coherus BioSciences, Inc.
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - -...
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 12, 2022 08:30 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th...
Coherus BioSciences Announces New Employment Inducement Grants
August 29, 2022 20:49 ET
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation...
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
August 04, 2022 16:01 ET
|
Coherus BioSciences, Inc.
– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of...